Integra Lifesciences Holdings Stock Earnings Reports

Integra reported a strong Q1 2026: revenue of $392M (reported +2.4%, organic +1.3%) and adjusted EPS of $0.54, both above the high end of prior guidance. Management reiterated full-year revenue guidance of $1.66B–$1.70B and raised full-year adjusted EPS guidance to $2.40–$2.50 (a $0.10 increase) driven by a favorable tariff outcome and improved execution. Gross margin expanded to 64.1% (up 190 bps YoY) and adjusted EBITDA margin improved to 19.4%; operating cash flow for the quarter was $9.8M and net debt stood at $1.6B with leverage of 4.1x (target 2.5–3.5x by year-end 2026).

Operational and strategic highlights: leadership change with Stuart Essig resuming CEO duties (retaining Chairman role) and appointment of Mike McBreen as Chief Commercial Officer to strengthen commercial focus; ongoing Compliance Master Plan and remediation work with improving supply reliability; Braintree facility start of production expected by end of June and SurgiMend relaunch planned by year-end; PMA submissions/approvals for SurgiMend and DuraSorb anticipated in 2027. Tissue Reconstruction was the growth engine in Q1 (organic +6.4%), led by Integra Skin, DuraSorb and PriMatrix; Specialty Surgery was roughly flat organically with pockets of strength in neurosurgery and capital equipment (CUSA).

Reimbursement and market dynamics: recent CMS outpatient skin-substitute reimbursement changes primarily affect outpatient markets (only ~10% of Integra’s wound-reconstruction revenue), while ~90% of wound-reconstruction revenue is inpatient and not impacted. Management believes Integra’s portfolio is well positioned competitively under the new reimbursement framework.

Financial posture and priorities: company expects sequential revenue step-up through the year (Q2 above Q1, Q3 roughly in-line with Q2, Q4 stronger), full-year gross margin target ~62.5% with quarter-to-quarter variability, continued focus on transformation and margin improvement, and an explicit near-term priority on debt reduction and leverage normalization before pursuing larger M&A (any future M&A would be in-core markets). Management emphasized disciplined, customer- and execution-focused commercial rollout as supply normalizes and previously pulled products are methodically relaunched.